Rosanna Tarricone, MSc, PhD, is Associate Professor in Public Administration at Bocconi University, Milan and Director of the Centre for Research on Health and Social Care (CeRGAS). She graduated in Business Administration at Bocconi University and holds an MSc in Health Services Management and PhD in Public Health, both from the London School of Hygiene and Tropical Medicine, University of London, UK. Her main areas of research are: health care management, economic analysis of health care services, health policy and health technology assessment (HTA). More recently, Rosanna has focused on medical devices, a class of health technologies whose assessment is often considered more challenging than other technologies such as pharmaceuticals. She has recently been the leader of a large, three-year EU-funded research project “MedtecHTA,” that has made recommendations on how to improve methods for assessing the effectiveness and cost-effectiveness of medical devices. Rosanna also serves as advisor for the Ministry of Health of Italy and several public and private entities in Italy and abroad.
ISPOR VISION Statement by Rosanna Tarricone, MSc, PhD
ISPOR is a scientific society that has massively contributed to the advancement of methods and applied research by engaging a wide range of professionals ranging from academics, practitioners, and decision-makers. ISPOR’s endeavor in fostering and incentivizing students’ interest in the field of outcome research and economic evaluation in health care makes the society even more special and I am proud to be a member. But what makes ISPOR unique is its unceasing endeavor for new challenges, for reaching and exceeding current research frontiers. Therefore, if elected to the Board of Directors I will work to help ISPOR extend its membership and activities in two constituencies that are at an important stage in their use of economic evaluation and outcomes research. The first constituency is Southern Europe, which to date has fallen behind Northern Europe in its production and, more importantly, use of these studies. The second constituency is medical devices, which comprise a wide range of technologies ranging from diagnostics to implantable therapeutic devices. These technologies differ from others, namely drugs, in several respects such as their regulation and procurement, but also for their critical interaction with end-users that affects costs and outcomes of health procedures and, at the same time, often leads to product modifications and incremental innovations. Important advances have been already made to better understand the particular features medical devices and how devices can be better assessed by appropriate methods. However, several important research questions remain unanswered and a larger community needs to be engaged to respond to these urgent research needs. I believe ISPOR is the right place to do so but, more importantly, the only society that can do so. I would be very honored to be part of the ISPOR Board of Directors. My vision is that ISPOR uses its resources to expand its research and policy interests, which have been so successful in the field of pharmaceuticals, to new countries and new classes of technologies where it has yet to have a major impact.